Novo Nordisk

News

Lilly goes toe-to-toe with Novo Nordisk on obesity

Eli Lilly has raised the stakes in its looming battle with Novo Nordisk in the market for obesity drugs, planning a clinical trial that will directly compare its new thera

News

Novo Nordisk, Aspect sign $2.6bn diabetes cell therapy deal

Novo Nordisk has put $75 million down on the table to partner Canadian biotech Aspect Biosystems’ cell-based therapies for diabetes and obesity.

News

CHMP backs obesity drug Wegovy for teens

Novo Nordisk’s sought-after obesity drug Wegovy could be approved in the EU shortly for use in adolescents as well as adults.

Market Access

Capping the cost of insulin: altruistic or strategic?

The price of insulin has become one of the most talked about issues across the pharma industry.

News

Novo Nordisk suspended from ABPI after code breach

The two-year ban reflects "serious breaches” of the trade organisation’s code of practice.

News

Novo Nordisk shadows Lilly with insulin price cut plan

Danish drugmaker says it will reduce the price of its insulin products in the US by up to 75%.

Lilly goes toe-to-toe with Novo Nordisk on obesity

Novo Nordisk, Aspect sign $2.6bn diabetes cell therapy deal

CHMP backs obesity drug Wegovy for teens

Capping the cost of insulin: altruistic or strategic?

Novo Nordisk suspended from ABPI after code breach

Novo Nordisk shadows Lilly with insulin price cut plan

Dexcom is first to join FDA/CMS health tech pilot

Discover a new era of healthcare panel engagement: Grounded ...

Novo Nordisk

Editor's Picks